The Top Five Papers of 2020 for General Internists

Main Article Content

Gabriel Huard
Olivier St-Laurent

Keywords

COVID; Randomized Controlled Trial; lung injury

Abstract

The Canadian Society of Internal Medicine (CSIM) held an annual session to present the “Top 5 papers” influencing the practice of general internists. We reviewed major journal publications from January 2020 to November 2020 to come up with approximately 10 articles we considered practice changing trials for general internists. Out of those papers, we decided to present the five we considered were most relevant by addressing frequent pathologies seen in practice, were methodologically well conducted, and had the potential to sustainably modify practice guidelines. The references to the papers that were not retained are presented in the bibliography section for the reader’s interest. This article aims to present those top five papers of 2020, and to review their strengths and limitations. These articles were also discussed at the CSIM Virtual Educational Activity on October 15, 2020 and in the BaladoCritique podcast.


Résumé
La Société canadienne de médecine interne (SCMI) a tenu une séance annuelle pour présenter les « cinq meil-leurs articles » qui influencent la pratique des internistes généralistes. Nous avons examiné les publications des principales revues publiées entre janvier 2020 et novembre 2020 pour en arriver à proposer environ dix articles que nous avons considérés comme des essais pouvant influencer la pratique des internistes généralistes. Parmi ces articles, nous avons décidé d’en présenter cinq qui, selon nous, sont les plus pertinents en abordant des pathologies fréquemment observées dans la pratique, sont bien menés sur le plan de la méthodologie et ont le potentiel de modifier de façon durable les directives de pratique. Les références des articles qui n’ont pas été retenus figurent dans la bibliographie pour l’intérêt du lecteur. Cet article vise à présenter les cinq meilleurs articles de 2020 et à examiner leurs forces et leurs limites. Ces articles ont également fait l’objet de discussions lors de l’activité éducative virtuelle de la SCMI qui s’est tenue le 15 octobre 2020 et dans un épisode du BaladoCritique.

Abstract 359 | PDF Downloads 124 XML Downloads 18 HTML Downloads 33

References

1. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—Preliminary report. N Engl J Med. 2020;384:693–704. http://dx.doi.org/10.1056/NEJMoa 2021436
2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052. http://dx.doi.org/10.1001/jama.2020. 6775
3. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treat-ment of venous Thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–607. http://dx.doi.org/10.1056/NEJMoa1915103
4. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous Thromboembolism: Results of a randomized trial (SELECT-D). JCO. 2018;36(20):2017–23. http://dx.doi.org/10.1200/JCO.2018.78.8034
5. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous Thromboembolism. N Engl J Med. 2018;378(7):615–24. http://dx.doi.org/10.1056/NEJMoa1711948
6. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838– 47. http://dx.doi.org/10.1056/NEJMoa2021372
7. Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505. http://dx.doi.org/10.1056/NEJMoa191 2388
8. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10. http://dx.doi.org/10.1016/j.jacc.2012.10.027
9. Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: The Australian COPS randomized clinical trial. Circulation. 2020;142(20):1890–900. http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050771
10. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004. http://dx.doi.org/10.1056/NEJMoa20 00052
11. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–30. http://dx.doi.org/10.1056/NEJMoa1709 118
12. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. http://dx.doi.org/10.1056/NEJ Moa2024816
13. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. http://dx.doi.org/10.1056/NEJMoa1811744
14. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm- control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383(14):1305–16. http://dx.doi.org/10.1056/NEJMoa2019422
15. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29. http://dx.doi.org/10.1056/NEJMoa202 5845
16. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–13. http://dx.doi.org/10.1056/NEJMoa1911793
17. Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207–17. http://dx.doi.org/10.1056/NEJMoa 1916870
18. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395–407. http://dx.doi.org/10.1056/NEJMoa191 5922
19. Kearon C, de Wit K, Parpia S, et al. Diagnosis of pulmonary embolism with d-dimer adjusted to clinical probability. N Engl J Med. 2019;381(22):2125–34. http://dx.doi.org/10.1056/NEJMoa1909159
20. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24. http://dx.doi.org/10.1056/NEJMoa202 2190
21. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—Final report. N Engl J Med. 2020;383(19):1813–1826. http://dx.doi.org/10.1056/NEJMoa20 07764